
- /
- Supported exchanges
- / US
- / PRTC.NASDAQ
PureTech Health PLC (PRTC NASDAQ) stock market data APIs
PureTech Health PLC Financial Data Overview
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get PureTech Health PLC data using free add-ons & libraries
Get PureTech Health PLC Fundamental Data
PureTech Health PLC Fundamental data includes:
- Net Revenue: 4 828 K
- EBITDA: -134 062 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-04-25
- EPS/Forecast: -1.98
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PureTech Health PLC News

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY)...


PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, January 03, 2024--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of pati...

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adj...

PureTech Year End Update and Outlook for 2024
Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balan...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.